A phase 2 study of SRT501 (resveratrol) with bortezomib for patients with relapsed and or refractory multiple myeloma

被引：172
|
作者：
Popat, Rakesh [1 ,2 ]
Plesner, Torben [3 ]
Davies, Faith [4 ]
Cook, Gordon [5 ]
Cook, Mark [6 ]
Elliott, Peter [7 ]
Jacobson, Eric [7 ]
Gumbleton, Todd [1 ]
Oakervee, Heather [1 ]
Cavenagh, Jamie [1 ]
机构：
[1] St Bartholomews Hosp, London, England
[2] UCL Canc Inst, London, England
[3] Vejle Hosp, Vejile, Denmark
[4] Royal Marsden Hosp, Surrey, England
[5] St James Hosp, Leeds LS9 7TF, W Yorkshire, England
[6] Queen Elizabeth Hosp, Birmingham B15 2TH, W Midlands, England
[7] GSK Co, Sirtris, Cambridge, MA USA
来源：
BRITISH JOURNAL OF HAEMATOLOGY | 2013年 / 160卷 / 05期
关键词：
myeloma; clinical trials; renal medicine; APOPTOSIS; PROTEINS;
D O I：
10.1111/bjh.12154
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：714 / 717
页数：4
相关论文
共 50 条
  • [1] A phase 2 study of bortezomib in relapsed, refractory myeloma
    Richardson, PG
    Barlogie, B
    Berenson, J
    Singhal, S
    Jagannath, S
    Irwin, D
    Rajkumar, SV
    Srkalovic, G
    Alsina, M
    Alexanian, R
    Siegel, D
    Orlowski, RZ
    Kuter, D
    Limentani, SA
    Lee, S
    Hideshima, T
    Esseltine, DL
    Kauffman, M
    Adams, J
    Schenkein, DP
    Anderson, KC
    NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (26): : 2609 - 2617
  • [2] Phase 2 trial of ixazomib in patients with relapsed multiple myeloma not refractory to bortezomib
    S K Kumar
    B LaPlant
    V Roy
    C B Reeder
    M Q Lacy
    M A Gertz
    K Laumann
    M A Thompson
    T E Witzig
    F K Buadi
    C E Rivera
    J R Mikhael
    P L Bergsagel
    P Kapoor
    L Hwa
    R Fonseca
    A K Stewart
    A Chanan-Khan
    S V Rajkumar
    A Dispenzieri
    Blood Cancer Journal, 2015, 5 : e338 - e338
  • [3] Phase 2 trial of ixazomib in patients with relapsed multiple myeloma not refractory to bortezomib
    Kumar, S. K.
    LaPlant, B.
    Roy, V.
    Reeder, C. B.
    Lacy, M. Q.
    Gertz, M. A.
    Laumann, K.
    Thompson, M. A.
    Witzig, T. E.
    Buadi, F. K.
    Rivera, C. E.
    Mikhael, J. R.
    Bergsagel, P. L.
    Kapoor, P.
    Hwa, L.
    Fonseca, R.
    Stewart, A. K.
    Chanan-Khan, A.
    Rajkumar, S. V.
    Dispenzieri, A.
    BLOOD CANCER JOURNAL, 2015, 5 : e338 - e338
  • [4] A phase 2 study of ibrutinib in combination with bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma
    Hajek, Roman
    Pour, Ludek
    Ozcan, Muhit
    Sanchez, Jesus Martin
    Sanz, Ramon Garcia
    Anagnostopoulos, Achilles
    Oriol, Albert
    Cascavilla, Nicola
    Terjung, Andreas
    Lee, Yihua
    Briso, Eva M.
    Dobkowska, Edyta
    Hauns, Bernhard
    Spicka, Ivan
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2020, 104 (05) : 435 - 442
  • [5] TANESPIMYCIN AND BORTEZOMIB IN PATIENTS WITH RELAPSED AND RELAPSED AND REFRACTORY MULTIPLE MYELOMA: FINAL RESULTS OF A PHASE 1/2 STUDY
    Richardson, P. G.
    Chanan-Khan, A.
    Lonial, S.
    Krishnan, A.
    Carroll, M.
    Alsina, M.
    Albitar, M.
    Berman, D.
    Szatrowski, T.
    Kaplita, S.
    Anderson, K. C.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 152 - 153
  • [6] Phase Ib Study of Panobinostat and Bortezomib in Relapsed or Relapsed and Refractory Multiple Myeloma
    San-Miguel, Jesus F.
    Richardson, Paul G.
    Guenther, Andreas
    Sezer, Orhan
    Siegel, David
    Blade, Joan
    LeBlanc, Richard
    Sutherland, Heather
    Sopala, Monika
    Mishra, Kaushal K.
    Mu, Song
    Bourquelot, Priscille M.
    Victoria Mateos, Maria
    Anderson, Kenneth C.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (29) : 3696 - +
  • [7] Tanespimycin and bortezomib combination treatment in patients with relapsed or relapsed and refractory multiple myeloma: results of a phase 1/2 study
    Richardson, Paul G.
    Chanan-Khan, Asher A.
    Lonial, Sagar
    Krishnan, Amrita Y.
    Carroll, Michael P.
    Alsina, Melissa
    Albitar, Maher
    Berman, David
    Messina, Marianne
    Anderson, Kenneth C.
    BRITISH JOURNAL OF HAEMATOLOGY, 2011, 153 (06) : 729 - 740
  • [8] Bortezomib in Relapsed/Refractory Multiple Myeloma
    Shen, Z.
    Wang, L.
    Yan, H.
    CLINICAL LYMPHOMA & MYELOMA, 2009, 9 : S62 - S62
  • [9] PANORAMA 2: A PHASE II STUDY OF PANOBINOSTAT IN COMBINATION WITH BORTEZOMIB AND DEXAMETHASONE IN PATIENTS WITH RELAPSED AND BORTEZOMIB-REFRACTORY MULTIPLE MYELOMA
    Richardson, P.
    Alsina, M.
    Weber, D.
    Coutre, S.
    Lonial, S.
    Gasparetto, C.
    Warsi, G.
    Ondovik, M.
    Mukhopadhyay, S.
    Paley, C.
    Schlossman, R.
    HAEMATOLOGICA, 2012, 97 : 338 - 338
  • [10] COMBINED VORINOSTAT AND BORTEZOMIB IN BORTEZOMIB-REFRACTORY PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: INTERIM ANALYSIS OF A PHASE IIB STUDY
    Siegel, D.
    Jagannath, S.
    Lonial, S.
    Dimopoulos, M.
    Yoon, S. S.
    Graef, T.
    Pitrangelo, D.
    Lupinacci, L.
    Reiser, D.
    Anderson, K.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 156 - 157
12345